Keymed Biosciences (HKG:2162) swung to an attributable loss of 336.7 million yuan in the first half from 47.0 million yuan in the year-ago period, according to a Tuesday filing with the Hong Kong Stock Exchange.
The drug company swung to a loss per share of 1.29 yuan from EPS of 0.18 yuan in the previous year.
Revenue plunged 83% to 54.7 million yuan from 327.1 million yuan a year earlier.
Shares rose nearly 2% on Wednesday's close.
Price (HKD): $32.55, Change: $+0.50, Percent Change: +1.56%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments